TCT 2022: AMULET-IDE: 3-year Outcomes of Amulet Device in Pts With AF | Dr Dhanunjaya Lakkireddy

Подробнее о видео

Watch on Radcliffe Cardiology: *6u6u62*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2MzY3NjM5Ny4zMTUuMS4xNjYzNjc4MDQ3LjAuMC4w?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-10257&utm_content=tct_lakkireddy

Dr Dhanunjaya Lakkireddy (University of Kansas Hospital, Kansas City, US) joins us to discuss the safety and efficacy of the Amulet Left Atrial Appendage Occluder as suggested by the results of the AMULET-IDE Study.

AMULET-IDE was a prospective, multi-center study with a cohort of 1878 patients with non-valvular atrial fibrillation. Participants were randomized to receive either the Amulet device, or the commercially available WATCHMAN Left Atrial Appendage Closure. The safety and efficacy of the Amulet device was then monitored over a 5-year period.

Recorded remotely from Kansas City, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.